Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D. Bona, Adam Cuker, George Goshua

Blood (2024) 143 (22): 2332–2335.

https://doi.org/10.1182/blood.2024024209

Published: 2024

Includes: Supplemental data

Journal Articles

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Satoko Ito, Kunal C Potnis, Cecily Allen, Rhys Richmond, Christina Waldron, Giri Viswanathan, Robert D Bona, George Goshua

Blood (2023) 142 (Supplement 1): 492.

https://doi.org/10.1182/blood-2023-190420

Published: 2023

Journal Articles

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2023-188018

Published: 2023

Journal Articles

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Daniel Wang, Satoko Ito, Christina Waldron, Ayesha Butt, Ellen Zhang, Harlan M. Krumholz, Hanny Al-Samkari, George Goshua

Blood (2023) 142 (Supplement 1): 2312.

https://doi.org/10.1182/blood-2023-185340

Published: 2023

Journal Articles

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Christina Waldron, Satoko Ito, Daniel Wang, Giri Viswanathan, Ayesha Butt, George Goshua

Blood (2023) 142 (Supplement 1): 2317.

https://doi.org/10.1182/blood-2023-189957

Published: 2023

NARROW

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Email alerts

ASH Publications

American Society of Hematology

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only